Morocco has authorized the emergency use of Merck & Co's molnupiravir medication for COVID-19 patients, Moroccan state news agency reported on Friday, quoting Bushra Maddah, the drugs chief at the country's
health ministry.
Molnupiravir was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
Morocco reported 6,428 cases, and 13 deaths of the coronavirus on Friday, bringing the overall numbers to 990,057 and 14,896, respectively.
